The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Real-world insights into outcomes after severe immune-related toxicity in NSCLC
Umair Mahmood, BSc, MSc, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on a real world study investigating the predictors and outcomes of patients with non-small cell lung cancer (NSCLC) following severe immune checkpoint inhibitor toxicity. He highlights the need for better data on treatment management strategies for patients who develop severe adverse events, and notes that patients with lower baseline neutrophil-to-lymphocyte ratio, those receiving more cycles of immunosuppressive agents, and those with pneumonitis tend to have poorer outcomes. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
